loadpatents
name:-0.025499105453491
name:-0.028257131576538
name:-0.013426065444946
OBIKA; Satoshi Patent Filings

OBIKA; Satoshi

Patent Applications and Registrations

Patent applications and USPTO patent grants for OBIKA; Satoshi.The latest application filed is for "molecular targeted nucleic acid medicine for gastric cancer".

Company Profile
12.27.39
  • OBIKA; Satoshi - Ibaraki-shi Osaka
  • OBIKA; Satoshi - Osaka JP
  • OBIKA; Satoshi - Suita JP
  • OBIKA; Satoshi - Suita-shi JP
  • Obika; Satoshi - Minoo JP
  • OBIKA; Satoshi - Minoo-shi Osaka
  • Obika; Satoshi - Takatsuki N/A JP
  • Obika; Satoshi - Takatsuki-shi JP
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
Molecular Targeted Nucleic Acid Medicine For Gastric Cancer
App 20220282248 - KANDA; Mitsuro ;   et al.
2022-09-08
Production Of Bridged Artificial Nucleosides
App 20220177509 - BABA; Takeshi ;   et al.
2022-06-09
Nucleic Acid Compound And Oligonucleotide
App 20220169671 - OBIKA; Satoshi ;   et al.
2022-06-02
Antisense Oligonucleic Acid
App 20220170020 - OBIKA; Satoshi ;   et al.
2022-06-02
Antisense Nucleic Acid Targeting Pcsk9
App 20220160880 - Harada-Shiba; Mariko ;   et al.
2022-05-26
5'-modified Nucleoside And Nucleotide Using Same
App 20220127300 - OBIKA; Satoshi ;   et al.
2022-04-28
Nucleic acid compound and oligonucleotide
Grant 11,286,275 - Obika , et al. March 29, 2
2022-03-29
Antisense nucleic acid targeting PCSK9
Grant 11,273,222 - Harada-Shiba , et al. March 15, 2
2022-03-15
Antisense oligonucleic acid
Grant 11,261,440 - Obika , et al. March 1, 2
2022-03-01
.alpha.-synuclein expression inhibitor
Grant 11,234,995 - Nakamori , et al. February 1, 2
2022-02-01
Crosslinked Artificial Nucleic Acid Alna
App 20220002336 - SAWAMOTO; Hiroaki ;   et al.
2022-01-06
Chimeric Double-stranded Nucleic Acid
App 20210340540 - Yokota; Takanori ;   et al.
2021-11-04
Antisense Oligonucleotide Targeting Arl4c Molecule, And Nucleic Acid Drug Using Antisense Oligonucleotide
App 20210317459 - KIKUCHI; Akira ;   et al.
2021-10-14
Small Cell Lung Cancer Therapeutic Agent Containing Oligonucleotide
App 20210277398 - SHIMOJO; Masahito ;   et al.
2021-09-09
Chimeric double-stranded nucleic acid
Grant 11,034,955 - Yokota , et al. June 15, 2
2021-06-15
Antisense Nucleic Acid Targeting Pcsk9
App 20210170032 - Harada-Shiba; Mariko ;   et al.
2021-06-10
Antisense Nucleic Acid For Inhibiting Biosynthesis Of Chondroitin
App 20210102214 - OBIKA; Satoshi ;   et al.
2021-04-08
Bridged nucleic acid GuNA, method for producing same, and intermediate compound
Grant 10,961,269 - Obika , et al. March 30, 2
2021-03-30
ENA ANTISENSE OLIGONUCLEOTIDE FOR INHIBITION OF alpha-SYNUCLEIN EXPRESSION
App 20200172903 - NAKAMORI; Masayuki ;   et al.
2020-06-04
Nucleic Acid Compound And Oligonucleotide
App 20200055890 - OBIKA; Satoshi ;   et al.
2020-02-20
Antisense Oligonucleic Acid
App 20200056178 - OBIKA; Satoshi ;   et al.
2020-02-20
Chimeric Double-stranded Nucleic Acid
App 20190270996 - YOKOTA; TAKANORI ;   et al.
2019-09-05
Oligonucleotide and artificial nucleoside having guanidine bridge
Grant 10,377,789 - Obika , et al. A
2019-08-13
Chimeric double-stranded nucleic acid
Grant 10,337,006 - Yokota , et al.
2019-07-02
Chimeric double-stranded nucleic acid
Grant 10,329,567 - Yokota , et al.
2019-06-25
Double-stranded antisense nucleic acid with exon-skipping effect
Grant 10,190,117 - Yokota , et al. Ja
2019-01-29
a-SYNUCLEIN EXPRESSION INHIBITOR
App 20190008886 - NAKAMORI; Masayuki ;   et al.
2019-01-10
Chimeric Double-stranded Nucleic Acid
App 20180320181 - Yokota; Takanori ;   et al.
2018-11-08
Crosslinked Nucleic Acid Guna, Method For Producing Same, And Intermediate Compound
App 20180251488 - OBIKA; Satoshi ;   et al.
2018-09-06
Chimeric Double-stranded Nucleic Acid
App 20180073024 - YOKOTA; TAKANORI ;   et al.
2018-03-15
Chimeric double-stranded nucleic acid
Grant 9,816,089 - Yokota , et al. November 14, 2
2017-11-14
Antisense Antineoplastic Agent
App 20170211073 - Nakano; Kenji ;   et al.
2017-07-27
Crosslinked nucleoside and nucleotide
Grant 9,611,479 - Obika , et al. April 4, 2
2017-04-04
Crosslinked Nucleoside And Nucleotide
App 20170044528 - OBIKA; Satoshi ;   et al.
2017-02-16
Double-stranded Antisense Nucleic Acid With Exon-skipping Effect
App 20160130583 - YOKOTA; Takanori ;   et al.
2016-05-12
Nucleoside And Nucleotide Having Sulfonamide Structure
App 20150337002 - OBIKA; Satoshi ;   et al.
2015-11-26
Oligonucleotide And Artificial Nucleoside Having Guanidine Bridge
App 20150266917 - Obika; Satoshi ;   et al.
2015-09-24
Oligonucleotide, and therapeutic agent for dyslipidemia containing oligonucleotide as active ingredient
Grant 9,127,280 - Obika , et al. September 8, 2
2015-09-08
Oligonucleotide And Therapeutic Agent For Hyperlipidemia Containing Same As Active Ingredient
App 20140323709 - Obika; Satoshi ;   et al.
2014-10-30
Chimeric Double-stranded Nucleic Acid
App 20140302603 - Yokota; Takanori ;   et al.
2014-10-09
.sup.18F-labeled azide compound, reagent for .sup.18F-labeling and method for .sup.18F-labeling of alkyne compound using same
Grant 8,680,260 - Watanabe , et al. March 25, 2
2014-03-25
Bicyclonucleoside and oligonucleotide analogues
Grant RE44,779 - Imanishi , et al. February 25, 2
2014-02-25
Bridged artificial nucleoside and nucleotide
Grant 8,541,562 - Obika , et al. September 24, 2
2013-09-24
Oligonucleotide, And Therapeutic Agent For Dyslipidemia Containing Oligonucleotide As Active Ingredient
App 20130172402 - Obika; Satoshi ;   et al.
2013-07-04
Bridged Artificial Nucleoside And Nucleotide
App 20120208991 - Obika; Satoshi ;   et al.
2012-08-16
18f-labeled Azide Compound, Reagent For 18f-labeling And Method For 18f-labeling Of Alkyne Compound Using Same
App 20120101266 - Watanabe; Yasuyoshi ;   et al.
2012-04-26
Bicyclonucleoside analogues
Grant 7,994,145 - Imanishi , et al. August 9, 2
2011-08-09
Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
Grant 7,615,619 - Imanishi , et al. November 10, 2
2009-11-10
Artificial nucleic acids of n-o bond crosslinkage type
Grant 7,427,672 - Imanishi , et al. September 23, 2
2008-09-23
Novel bicyclonucleoside analogues
App 20070270370 - Imanishi; Takeshi ;   et al.
2007-11-22
Novel artificial nucleic acids of n-o bond crosslinkage type
App 20070167387 - Imanishi; Takeshi ;   et al.
2007-07-19
Bicyclonucleoside analogues
Grant 7,217,805 - Imanishi , et al. May 15, 2
2007-05-15
Nucloeside analogues and oligonucleotide derivative comprising nucleotide analogue thereof
App 20060166908 - Imanishi; Takeshi ;   et al.
2006-07-27
Nucleoside analogs and oligonucleotide derivatives containing these analogs
Grant 7,053,199 - Imanishi , et al. May 30, 2
2006-05-30
Nucleoside analogues whose sugar moieties are bound in s-form and oligonucleotide derivatives comprising nucleotide analogues thereof
App 20050176941 - Imanishi, Takeshi ;   et al.
2005-08-11
Novel anitsense oligonucleotide derivatives against to hepatitis c virus
App 20050059617 - Imanishi, Takeshi ;   et al.
2005-03-17
Novel nucleoside analogs and oligonucleotide derivatives containing these analogs
App 20040192918 - Imanishi, Takeshi ;   et al.
2004-09-30
Bicyclonucleoside and oligonucleotide analogue
Grant 6,770,748 - Imanishi , et al. August 3, 2
2004-08-03
Novel bicyclonucleoside analogues
App 20040143114 - Imanishi, Takeshi ;   et al.
2004-07-22
Novel bicyclonucleoside and oligonucleotide analogue
App 20030105309 - Imanishi, Takeshi ;   et al.
2003-06-05
Bicyclonucleoside and oligonucleotide analogues
Grant 6,268,490 - Imanishi , et al. July 31, 2
2001-07-31

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed